Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,577 shares of the biotechnology company's stock, valued at approximately $3,217,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. Bank of Nova Scotia purchased a new stake in Repligen during the 2nd quarter valued at about $3,547,000. Avidity Partners Management LP raised its holdings in Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company's stock valued at $9,166,000 after acquiring an additional 27,500 shares during the last quarter. Swedbank AB purchased a new position in Repligen in the 4th quarter worth approximately $4,146,000. Global Retirement Partners LLC acquired a new position in shares of Repligen during the 2nd quarter worth approximately $655,000. Finally, B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Repligen in the second quarter valued at approximately $3,597,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have weighed in on RGEN. Royal Bank Of Canada initiated coverage on Repligen in a research note on Thursday, May 14th. They set an "outperform" rating and a $160.00 price objective on the stock. Weiss Ratings upgraded Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 13th. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Jefferies Financial Group reissued a "hold" rating and issued a $142.00 price objective on shares of Repligen in a report on Tuesday, May 5th. Finally, Zacks Research raised shares of Repligen from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $166.43.
Get Our Latest Analysis on Repligen
Repligen Stock Down 3.2%
NASDAQ:RGEN opened at $176.27 on Friday. The stock's fifty day moving average is $151.99 and its two-hundred day moving average is $133.09. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $9.95 billion, a price-to-earnings ratio of 241.47, a price-to-earnings-growth ratio of 3.32 and a beta of 1.03.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.
Insider Buying and Selling
In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company's stock, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.60% of the stock is owned by corporate insiders.
Repligen Company Profile
(
Free Report)
Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
